Human leukocyte antigen–DR isotype (major histocompatibility complex class II) expression in different types of endometriosis

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Disorders of the immune system, which regulates adhesion, invasion, proliferation, apoptosis, and neoangiogenesis, are essential in the development of endometriosis. At the same time, a significant role is assigned to the immunogenetic aspects of the progression of endometriosis, in particular, the influence of major histocompatibility complex, or human leukocyte antigens, on the regulation of the immune system in this disease. However, characteristic features of its expression in different types of endometriosis are poorly understood.

AIM: The aim of this study was to determine the human leukocyte antigen–DR isotype (major histocompatibility complex class II) (HLA-DR) expression characteristics in endometrioid heterotopias in different types of endometriosis such as adenomyosis, endometrial ovarian cysts, and extragenital endometriosis.

METHODS: This retrospective study was performed based on morphological and immunohistochemical studies of surgical material. The latter was carried out using the standard avidin-biotin complex method using mouse monoclonal antibodies specific to HLA-DR (class II).

RESULTS: The study included 329 women aged 18 to 47 years who underwent surgical interventions for endometriosis of various organ localizations: 98 cases of internal genital endometriosis (adenomyosis), 196 cases of endometrial ovarian cysts, and 35 cases of extragenital endometriosis (21 cases of postoperative scar endometriosis and 14 cases of endometriosis of various parts of the intestine). Regardless of the organ localization of endometriosis, a clear pattern of HLA-DR (class II) expression was found. HLA-DR positive cells were found in the stroma of adenomyosis foci, in the capsules of endometrial ovarian cysts, and in extragenital heterotopias. They were more common in postoperative scar endometriosis—79 [75; 104], intestinal endometriosis—55 [50; 59], adenomyosis—56 [32; 97], and in endometrial ovarian cysts, their expression value was 14 [10; 63]. The glandular epithelium in endometrial heterotopias with signs of proliferation or secretion was HLA-DR negative in all the studied types of endometriosis—in adenomyosis, postoperative scar endometriosis, and intestinal endometriosis. Positive HLA-DR (class II) expression was found only in the epithelial lining of cystically transformed glands in adenomyosis foci and extragenital sites of endometriosis. The largest number of HLA-DR positive epithelial cells was found in the epithelial lining of endometrial ovarian cysts, the expression intensity being weak in 12.3%, intermediate in 72.3%, and strong in 15.4% of cases.

CONCLUSION: The data obtained suggest that the HLA-DR positive phenotype of endometriosis may reflect a specific morphogenesis and abnormalities in the cell genome associated with chronic inflammation, which is important in the prognosis of the clinical course of the disease. Further comprehensive clinical, morphological, and molecular genetic studies are required.

全文:

受限制的访问

作者简介

Victoria Pechenikova

North-Western State Medical University named after I.I. Mechnikov

编辑信件的主要联系方式.
Email: p-vikka@mail.ru
ORCID iD: 0000-0001-5322-708X
SPIN 代码: 9603-5645

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Saint Petersburg

Nikol Pertovskaia

North-Western State Medical University named after I.I. Mechnikov

Email: dr.ramzaeva@mail.ru
ORCID iD: 0000-0001-6849-5335
SPIN 代码: 7769-1969

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Saint Petersburg

Artem Safronov

North-Western State Medical University named after I.I. Mechnikov

Email: Safr-Ar@yandex.ru
ORCID iD: 0000-0001-6625-2479
SPIN 代码: 6180-8844
俄罗斯联邦, Saint Petersburg

参考

  1. Adamyan LV, Arslanyan KN, Loginova ON, et al. Immunological aspects of endometriosis: review of the literature. Lechaschi vrach. 2020;(4):37–47. (In Russ.) doi: 10.26295/OS.2020.29.10.007
  2. Symons LK, Miller JE, Kay VR, et al. The immunopathophysiology of endometriosis. Trends Mol Med. 2018;24(9):748–762. EDN: YHTFMD doi: 10.1016/j.molmed.2018.07.004
  3. Chiang CM, Hill JA. Localization of T cells, interferon-gamma and HLA-DR in eutopic and ectopic human endometrium. Gynecol Obstet Invest. 1997;43(4):245–250. doi: 10.1159/000291866
  4. Ota H, Igarashi S. Expression of major histocompatibility complex class II antigen in endometriotic tissue in patients with endometriosis and adenomyosis. Fertil Steril. 1993;60(5):834–838. doi: 10.1016/s0015-0282(16)56284-0
  5. Baka S, Frangou-Plemenou M, Panagiotopoulou E, et al. The expression of human leukocyte antigens class I and II in women with endometriosis or adenomyosis. Gynecol Endocrinol. 2011;27(6):419–424. doi: 10.3109/09513590.2010.495429
  6. Guarene M, Capittini C, De Silvestri A, et al. Targeting the immunogenetic diseases with the appropriate HLA molecular typing: critical appraisal on 2666 patients typed in one single centre. Biomed Res Int. 2013;2013:904247. doi: 10.1155/2013/904247
  7. Nordquist H, Jamil RT. Biochemistry, HLA Antigens. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. [cited 2024 Dec 26]. Available from: https://pubmed.ncbi.nlm.nih.gov/31536268/
  8. Troshina EA, Yukina MYu, Nuralieva NF, et al. The role of HLA genes: from autoimmune diseases to COVID-19. Problems of Endocrinology. 2020;66(4):9–15. EDN: FXVGYQ doi: 10.14341/probl12470
  9. Ho HN, Chao KH, Chen HF, et al. Peritoneal natural killer cytotoxicity and CD25+ CD3+ lymphocyte subpopulation are decreased in women with stage III-IV endometriosis. Hum Reprod. 1995;10(10):2671–2675. EDN: IPDEVX doi: 10.1093/oxfordjournals.humrep.a135765
  10. Králíčková M, Vetvicka V. Immunological aspects of endometriosis: a review. Ann Transl Med. 2015;3(11):153. EDN: YYGRBR doi: 10.3978/j.issn.2305-5839.2015.06.08
  11. Yan J, Zhou L, Liu M, et al. Single-cell analysis reveals insights into epithelial abnormalities in ovarian endometriosis. Cell Rep. 2024;43(3):113716. EDN: YOHNAR doi: 10.1016/j.celrep.2024.113716
  12. Liu Y, Luo L, Zhao H. Immunohistochemical study of HLA-DR antigen in endometrial tissue of patients with endometriosis. J Huazhong Univ Sci Technolog Med Sci. 2002;22(1):60–61. doi: 10.1007/BF02904791
  13. Maxwell C, Kilpatrick DC, Haining R, et al. No HLA-DR specificity is associated with endometriosis. Tissue Antigens. 1989;34(2):145–147. doi: 10.1111/j.1399-0039.1989.tb01729.x
  14. Koumantakis EE, Panayiotides JG, Goumenou AG, et al. Different HLA-DR expression in endometriotic and adenomyotic lesions: correlation with transvaginal ultrasonography findings. Arch Gynecol Obstet. 2010;281(5):851–856. doi: 10.1007/s00404-009-1168-z
  15. Ellinidi VN, Smaglenko EA, Pechenikova VA, et al. Human leukocyte antigen, isotype DR (HLA-DR) expression in the normal endometrium and in endometrial pathology. Journal of Obstetrics and Women’s Diseases. 2024;73(5):96–104. EDN: FSOUXH doi: 10.17816/JOWD632930

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Adenomyosis. Positive expression of HLA-DR by cytogenic stroma cells, zoom ×200.

下载 (123KB)
3. Fig. 2. Adenomyosis. Positive expression of HLA-DR by epithelial cells of the lining of cystically transformed glands and cytogenic stroma cells, zoom ×200.

下载 (298KB)
4. Fig. 3. Ovarian endometriosis. Positive expression of HLA-DR by cytogenic stroma cells, the capsule, and epithelial cells of the endometrial cyst lining, zoom ×200.

下载 (135KB)
5. Fig. 4. Postoperative scar endometriosis. Expression of HLA-DR by cytogenic stroma cells and epithelial cells of the lining of the cystically transformed gland, zoom ×200.

下载 (133KB)
6. Fig. 5. Bowel endometriosis. Positive expression of HLA-DR by cytogenic stroma cells, zoom ×200.

下载 (130KB)

版权所有 © Eсо-Vector, 2025



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389
от 15.07.2002 г.